NCI’s Srivastava Receives Listwin Award

Dr. Sudhir Srivastava

Dr. Sudhir Srivastava received the 2022 Don Listwin Award for Outstanding Contributions to Cancer Early Detection. Srivastava is senior scientific officer and chief of the Cancer Biomarkers Research Branch in the Division of Cancer Prevention, National Cancer Institute (NCI). 

He established several transformative programs on translational research in cancer screening, early detection, risk assessment and enabling technologies including artificial intelligence (https://prevention.cancer.gov/research-groups/cancer-biomarkers/about-cancer-biomarkers) with a network of leading experts in medicine, science and computational biology that has advanced discoveries and revolutionized diagnostics.

Srivastava developed and implemented a novel approach to collaborative clinical research on cancer biomarkers through the establishment of the Early Detection Research Network (EDRN; www.cancer.gov/edrn), a flagship NCI program that has begun translating biomarkers into clinical tests. The network has been a pioneer in applying innovative technologies in the validation of cancer biomarkers as well as in the development of a national informatics infrastructure to support the research.

The award is named in honor of Listwin, founder and chair of the nonprofit Canary Foundation, which he established in 2004 after losing his mother to misdiagnosed ovarian cancer. He envisioned a world of simple and safe tests that could identify cancer at its earliest, most curable stage. In 2009, he partnered with Stanford to establish the Canary Center at Stanford—the first center in the world dedicated to cancer early detection.

Since its start, the foundation has raised more than $75 million to support early detection research. For details, visit https://www.earlydetectionresearch.com/award/.